To the best of our knowledge, this was the first study to incorporate the expression of Ki-67 and common clinical-pathological factors into a nomogram, to predict survival following first-line treatment in NSCLC with EGFR or KRAS mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.